Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Weight loss and metabolic effects of topiramate in overweight and obese type 2 diabetic patients: randomized double-blind placebo-controlled trial

International Journal of Obesity volume 31, pages 1140–1147 (2007)Cite this article

Abstract

Objective:

To examine the metabolic effects and body composition changes after topiramate treatment of obese type 2 diabetic patients (DM2) for 11 months.

Design and subjects:

Thirty-eight DM2 on diet or sulfonylurea treatment participated in this randomized double-blind placebo-controlled trial. Thirteen placebo-treated and nine topiramate-treated patients completed the trial. Patients were randomized to treatment with topiramate 96 mg b.i.d. or placebo (6-week run-in phase, 2-months titration phase, 9-months maintenance phase).

Measurements:

Insulin sensitivity was measured with euglycaemic hyperinsulinemic clamps. Weight, HbA1c, fasting glucose, blood lipids and safety variables were measured at regular intervals. Body composition was determined with computerized tomography. Meal tests were performed to evaluate postprandial glucose and insulin levels. Three-day diet recalls were carried out to evaluate energy ingestion.

Results:

The mean age was 58.6±7.1 years, body weight 98.1±16.1 kg, BMI 33.0±4.5 kg/m2, and glycosylated hemoglobin (HbA1c) 7.3±0.9%. In topiramate-treated patients, there were significant reductions in HbA1c (1.1±0.9%), fasting plasma glucose, body weight (−6.6±3.3%), as well as body fat, lean body mass, postprandial glucose and free fatty acid levels but there were no significant changes in insulin sensitivity. The daily average energy intake decreased more in the topiramate group than in the placebo group. Paresthesia and central nervous system-related side effects were the main causes for the dropout rate.

Conclusions:

Topiramate treatment of overweight DM2 reduced body weight and body fat, and was associated with a marked improvement in glycaemic control whereas no significant improvement in insulin-stimulated glucose uptake was demonstrated. Further studies are required to clarify whether this effect might occur through changes in insulin sensitivity in the liver and/or pancreatic insulin secretion.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Williamson DF, Vinicor F, Bowman BA . Primary prevention of type 2 diabetes mellitus by lifestyle intervention: implications for health policy. Ann Intern Med 2004; 140: 951–957.

    Article  PubMed  Google Scholar 

  2. Inzucchi SE . Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 2002; 287: 360–372.

    Article  CAS  PubMed  Google Scholar 

  3. Norris SL, Zhang X, Avenell A, Gregg E, Schmid CH, Curi K et al. Efficacy of pharmacotherapy for weight loss in adults with type 2 diabetes mellitus. A meta-analysis. Arch Intern Med 2004; 164: 1395–1404.

    Article  CAS  PubMed  Google Scholar 

  4. Astrup A, Caterson I, Zelissen P, Guy-Grand B, Carruba M, Levy B et al. Topiramate for long-term maintenance of weight loss induced by a low-calorie diet in obese subjects. Obes Res 2004; 12: 1658–1669.

    Article  CAS  PubMed  Google Scholar 

  5. Ben-Menachem E, Axelsen M, Johanson EH, Stagge A, Smith U . Predictors of weight loss in adults with topiramate-treated epilepsy. Obes Res 2003; 11: 556–562.

    Article  CAS  PubMed  Google Scholar 

  6. Bray GA, Hollander P, Klein S, Kushner R, Levy B, Fitchet M et al. A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. Obes Res 2003; 11: 722–733.

    Article  CAS  PubMed  Google Scholar 

  7. Wilding J, Gaal LV, Rissanen A, Vercruysse F, Fitchet M . A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects. Int J Obes Relat Metab Disord 2004; 28: 1399–1410.

    Article  CAS  PubMed  Google Scholar 

  8. Wilkes JJ, Nelson E, Osborne M, Demarest KT, Olefsky JM . Topiramate is an insulin sensitizing compound in vivo with direct effects on adipocytes in female ZDF rats. Am J Physiol Endocrinol Metab 2005; 288: E617–E624.

    Article  CAS  PubMed  Google Scholar 

  9. Gustafson B, Jack MM, Cushman SW, Smith U . Adiponectin gene activation by thiazolidinediones requires PPAR gamma 2, but not C/EBP alpha-evidence for differential regulation of the aP2 and adiponectin genes. Biochem Biophys Res Commun 2003; 308: 933–939.

    Article  CAS  PubMed  Google Scholar 

  10. DeFronzo RA, Tobin JD, Andres R . Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979; 237: E214–E223.

    CAS  PubMed  Google Scholar 

  11. Attvall S, Eriksson BM, Fowelin J, von Schenck H, Lager I, Smith U . Early posthypoglycemic insulin resistance in man is mainly an effect of beta-adrenergic stimulation. J Clin Invest 1987; 80: 437–442.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Lager I, Attvall S, Eriksson BM, von Schenck H, Smith U . Studies on the insulin-antagonistic effect of catecholamines in normal man. Evidence for the imoprtance of β2-receptors. Diabetologia 1986; 29: 409–416.

    Article  CAS  PubMed  Google Scholar 

  13. Kvist H, Chowdhury B, Grangård U, Tylén U, Sjöström L . Total and visceral adipose-tissue volumes derived from measurements with computerized tomography in adult men and women: predictive equations. Am J Clin Nutr 1988; 48: 1351–1361.

    Article  CAS  PubMed  Google Scholar 

  14. Sjöström L, Kvist H, Cederblad A, Tylen U . Determination of total adipose tissue and body fat in women by computed tomography, 40 K and tritium. Am J Physiol 1986; 250: E736–E745.

    PubMed  Google Scholar 

  15. Axelsen M, Eliasson B, Joheim E, Lenner RA, Taskinen MR, Smith U . Lipid intolerance in smokers. J Intern Med 1995; 237: 449–455.

    Article  CAS  PubMed  Google Scholar 

  16. Carvalho E, Jansson PA, Nagaev I, Wenthzel AM, Smith U . Insulin resistance with low cellular IRS-1 expression is also associated with low GLUT4 expression and impaired insulin-stimulated glucose transport. FASEB J 2001; 15: 1101–1103.

    CAS  PubMed  Google Scholar 

  17. Sopasakis VR, Sandqvist M, Gustafson B, Hammarstedt A, Schmelz M, Yang X et al. High local concentrations and effects on differentiation implicate interleukin-6 as a paracrine regulator. Obes Res 2004; 12: 454–460.

    Article  CAS  PubMed  Google Scholar 

  18. Salmenniemi U, Zacharova J, Ruotsalainen E, Vauhkonen I, Pihlajamaki J, Kainulainen S et al. Association of adiponectin level and variants in the adiponectin gene with glucose metabolism, energy expenditure and cytokines in offspring of type 2 diabetic patients. J Clin Endocrinol Metab 2005; 90: 4216–4223.

    Article  CAS  PubMed  Google Scholar 

  19. Husum H, Van Kammen D, Termeer E, Bolwig G, Mathe A . Topiramate normalizes hippocampal NPY-LI in flinders sensitive line ‘depressed’ rats and upregulates NPY, galanin, and CRH-LI in the hypothalamus: implications for mood-stabilizing and weight loss-inducing effects. Neuropsychopharmacology 2003; 28: 1292–1299.

    Article  CAS  PubMed  Google Scholar 

  20. Raskin P, Donofrio PD, Rosenthal NR, Hewitt DJ, Jordan DM, Xiang J et al. Topiramate vs placebo in painful diabetic neuropathy: analgesic and metabolic effects. Neurology 2004; 63: 865–873.

    Article  CAS  PubMed  Google Scholar 

  21. Liang Y, Chen X, Osborne M, DeCarlo SO, Jetton TL, Demarest K . Topiramate ameliorates hyperglycemia and improves glucose-stimulated insulin release in ZDF rats and db/db mice. Diab Obes Metabol 2005; 7: 360–369.

    Article  CAS  Google Scholar 

  22. Petersen KF, Dufour S, Befroy D, Lehrke M, Hendler RE, Shulman GI . Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with Type 2 diabetes. Diabetes 2005; 54: 603–608.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The skilful technical expertise by A Davidsson, RN, M Landén, and C Cullberg, RN, is gratefully acknowledged. This study was sponsored by Johnson & Johnson Pharmaceutical Research & Development, LLC.

Author information

Authors and Affiliations

  1. Lundberg Laboratory for Diabetes Research, Sahlgrenska University Hospital, Göteborg University, Göteborg, Sweden

    B Eliasson, S Gudbjörnsdottir & U Smith

  2. Department of Public Health and Caring Sciences, Family Medicine and Epidemiology Section, University Hospital, Uppsala, Sweden

    J Cederholm

  3. Johnson and Johnson Pharmaceutical Research and Development, Raritan, NJ, USA

    Y Liang

  4. Johnson & Johnson Pharmaceutical Research and Development, Beerse, Belgium

    F Vercruysse

Authors
  1. B Eliasson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S Gudbjörnsdottir
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J Cederholm
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Y Liang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. F Vercruysse
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. U Smith
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to B Eliasson.

Additional information

Conflict of interest statement

BE, SG, JC and US do not have any conflicts of interest. LY and FV are employees of Johnson & Johnson Pharmaceutical Research & Development LLC.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Eliasson, B., Gudbjörnsdottir, S., Cederholm, J. et al. Weight loss and metabolic effects of topiramate in overweight and obese type 2 diabetic patients: randomized double-blind placebo-controlled trial. Int J Obes 31, 1140–1147 (2007). https://doi.org/10.1038/sj.ijo.0803548

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.ijo.0803548

Keywords

This article is cited by

Search

Advanced search

Quick links